Impact of Hyperoxia During Cardiopulmonary

Phase 3CompletedNCT02819739

Centre Hospitalier Universitaire, Amiens330 enrolled

Overview

The hypothesis implies that this work is the use of hyperoxia during cardiopulmonary bypass by his heart preconditioning effect is associated with a lower incidence of cardiac arrhythmias (atrial fibrillation, tachycardia or ventricular fibrillation) and lesions of myocardial ischemia-reperfusion injury in cardiac surgery postoperative.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

330

Conditions

Cardiac Complications

Interventions

medical oxygenDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major patient ≥ 18 years * Patient operated cardiac surgery for myocardial revascularization (CABG) or surgical correction of valvular or combined surgery (CABG and valve disease) or ascending aortic surgery * Signed Consent * Affiliation to social security Exclusion Criteria: * Permanent atrial fibrillation * Cordarone therapy, * Pregnant woman * Patient under guardianship or trusteeship or private public law * Internal pacemaker * Hypothermia, * Patient refusal, * Cardiac surgery without extracorporal circulation (ECC), * Participation in another study.

Locations (2)

CHU Amiens-Picardie

Amiens, France

CHU Dijon-Bourgogne

Dijon, France

Outcomes

Primary Outcomes

Occurred within 15 days after surgery, disorders of heart rhythm (atrial fibrillation, tachycardia or ventricular fibrillation)

Time frame: 15 days after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.